Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits

NEW ORLEANS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data on the EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the American College of Cardiology Annual Scientific Session (ACC.26), demonstrating significant and sustained patient benefits including lower mortality when accounting for patient crossover, extending the findings presented at the European Society of Cardiology Congress (ESC 2025). The new TRISCEND II trial data presented today during.